Advanced Search

Study Preview



Study Title and Description

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.



Key Questions Addressed
6 Key Question 6. What is the effectiveness of currently recommended antiviral treatments in improving health outcomes in patients with HCV infection?
  • Comments Comments (
    0
    ) |
7 Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?
  • Comments Comments (
    0
    ) |
8 Key Question 8. What are the harms of currently recommended antiviral treatments?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
Author Kwo P., Gitlin N., Nahass R., Bernstein D., Etzkorn K., Rojter S., Schiff E., Davis M., Ruane P., Younes Z., Kalmeijer R., Sinha R., Peeters M., Lenz O., Fevery B., De La Rosa G., Scott J., Witek J.
Country Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University, Indianapolis, IN.
Year 2016
Numbers Pubmed ID: 26799692

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Key Questions 1-9


Results & Comparisons

No Results found.